Dec. 10, 2023 | ZIPCODE CELEBRATES DR. DREW WEISSMAN'S RECEIVING AWARD AT THE 2023 NOBLE PRIZE CEREMONEY

Boston, MA, USA – Zipcode Bio, a startup focusing on next-generation nucleic acid applications, congratulates its Co-Founder, Dr. Drew Weissman on receiving the 2023 Nobel Prize in Physiology or Medicine at the Nobel Prize Ceremony in Stockholm, Sweden. The company applauds Dr. Weissman for his exceptional contributions to mRNA technology.

Dr. Weissman has played a crucial role in shaping the company’s mission to develop innovative and cost-effective treatments. Leveraging precise genetic instructions, Zipcode Bio focuses on advancing targeted delivery solutions for nucleic acids, including mRNA and oligonucleotides, ensuring optimal therapeutic outcomes and tolerability.

“We are immensely proud of Dr. Drew Weissman for his well-deserved recognition with the 2023 Nobel Prize, acknowledging his pioneering contributions to mRNA technology. His vision and leadership have been pivotal in advancing next-generation nucleic acid applications with targeted delivery,” said Dr. Jason Zhang, Co-Founder and CEO at Zipcode Bio.

About Zipcode Bio: Zipcode Bio is a biotechnology company specializing in the development of next-generation nucleic acid applications that are accessible, widely distributable, and superior in efficacy and safety. The company's co-founders include Drew Weissman and Dr. Jason Zhang. The scientific strength is based on the co-founders’ deep knowledge in RNA medicine and breakthrough SHARP (Single-component Homogeneous Amphiphilic Routed Particles) technology. Zipcode Bio stands at the forefront of developing revolutionary solutions with the potential to transform patient care. The company has assembled a dynamic team committed to pushing scientific boundaries and developing novel therapeutics to address unmet healthcare needs. The dedication to innovation, precision, and accessibility underscores its mission to improve therapeutic outcomes and contribute to the evolution of global healthcare.